J&J Targeted Docs To Push Fentanyl Patch, Okla. Judge Hears
Law360 (May 30, 2019, 10:32 PM EDT) -- A regional sales director for Johnson & Johnson subsidiary Janssen called the company's self-described efforts to "target" and "influence" doctors into increasing prescriptions for its Duragesic fentanyl patch as the mere "education" of medical professionals during her hours on the stand in an Oklahoma bench trial Thursday.
For the entirety of the third day of the much-watched trial over liability in the opioid crisis, Oklahoma attorney Bradley Beckworth of Nix Patterson LLP examined Janssen regional business director Kimberly Deem-Eshleman.
Beckworth painstakingly went through numerous internal Janssen documents before Judge Thad Balkman, who is presiding over the landmark trial. These included a report written by...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!